Administration of mGlu5R antagonists have been associated with reduced striatal levels of phosphorylated ERK and MSK1 as well as weakened dyskinesia in experimental PD (Spigolon and Fisone, 2018; Sebastianutto et al., 2020; Rylander et al., 2009). This evidence concerns the gene RPS6KA5 and Parkinson disease.